Main > > >HEMATOLOGY.

---

Acquired Thrombotic Thrombocytopenic Purpura (aTTP). TREAT.: CaplacizuMAb.
EU Approval Date : 2018. 09.03.
USA Approval Date: 2019. 02.06.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 07.28.




Alinity h-series integrated system for hematology testing.
EU Approval Date: 2018. 01.02.
(*) Company: Abbott.
UpDate: 2018. 01.04.




Anemia. Iron Deficiency Anemia. (IDA).
TREAT.: Ferric Maltol Capsules.
DE Launch Date: ?
EU Approval Date: 2018. 03.27.
UK Launch Date : 2018. 12.05.
(*) Companies; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 12.06.




Anemia. Iron Deficiency Anemia. TREAT.: Ferumoxytol Injection.
USA Approval Date: 2018. 02.05.
(*) Company : AMAG Pharmaceuticals.
TradeMark: Feraheme
Web-Site : www.feraheme.com/
UpDate: 2018. 02.06.




Apixaban. AntiDote. (U)
EU Approval Date: 2019. 04.26.
USA Approval Date: 2018. 05.03.
(*) Company; Patents; TradeMarks &
Web-Site Available on Request
UpDate: 2020. 05.06.




Automated Recapping System.
automated, pneumatics-free, high-speed, benchtop recapper designed to safely and automatically recap "tubes" for storage or archiving.
(*) Company; Patents; TradeMark & Web-Site Available on
Request.
UpDate: 2018. 02.14.




Bleeding Control. Aminocaproic Acid Ta-
blets. Generics.
USA Approval Date: 2018. 12.03.
(*) Company: Vitruvias Therapeutics Inc.
UpDate: 2018. 12.04.




Blood Clot Prevention & TREAT.: Warfarin Sodium Tablets.
(*) Company : Bristol Myers Squibb.
Patent : Expired.
TradeMark: Coumadin.
Web-Site : www.coumadin.bmscustomerconnect.com
UpDate: 2018. 02.02.




CAD/PAD. Prevention of Atherothrombotic Events. Rivaroxaban Tablets.
EU Approval Date: 2018. 08.24.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 08.28.




Coagulation Factor VIIa (Recombinant).
Indications: - Acquired Hemophilia
- Congenital Factor VII Deficiency
- Congenital Hemophilia with Inhibitors.
- Glanzmann s Thrombasthenia Refractory to
Platelets.
Patent Expiration Date: 2010. 11.15.
(*) Company : Novo Nordisk.
TradeMark: NovoSeven RT.
Web-Site : www.novosevenrt.com
UpDate: 2018. 01.31.




Deep Vein Thrombosis (DVT). Prevention: Apixaban Tablets.
(After Hip or Knee Surgery).
Oral Factor Xa Inhibitor AntiCoagulant.
EU Approval Date: 2011. 05.20.
USA Approval Date: 2014. 03.14.
(*) Companies; Patents; TradeMark & Web-Site Available on
Request.
UpDate: 2018. 01.29.




Deep Vein Thrombosis (DVT). Prevention: Enoxaparin Sodium Injection. BRAND.
(After Hip or Knee Surgery).
low molecular weight heparin [LMWH]
Patent Expiration: 2004.
(*) Company : Sanofi Aventis US LLC.
TradeMark: Lovenox
Web-Site : www.lovenox.com
UpDate: 2018. 01.31.




Deep Vein Thrombosis (DVT). Prevention: Enoxaparin Sodium Injection. GENERIC.
(After Hip or Knee Surgery).
low molecular weight heparin [LMWH]
USA Approval Date: 2010. 07.
(*) Company : Momenta Pharmaceuticals
Web-Site: hwww.momentapharma.com/products/enoxaparin.php
UpDate: 2018. 01.31.




Deep Vein Thrombosis (DVT). Prevention: Fondaparinux Sodium.
(After Hip or Knee Surgery).
Synthetic Heparin.
Xa Inhibitor.
(*) Company : Aspen Holdings. www.aspenpharma.com
Patents : Expiration Year 2002
TradeMark: Arixtra.
Web-Site : www.aspenpharma.com/thrombosis/
UpDate: 2018. 02.01.




Deep Vein Thrombosis (DVT). Prevention: Rivaroxaban Tablets.
(After Hip or Knee Surgery).
Xa Inhibitor.
EU Approval Date : 2011. 12.19.
JP Approval Date : 2015. 09.24.
USA Approval Date: 2012. 11.02.
(*) Companies; Patents; TradeMark & Web-Site Available on
Request.
UpDate: 2018. 02.04.




Deep Vein Thrombosis (DVT). TREAT.:
Thrombectomy Device.
Extracting Large Clots from Large>
>vessels without the need for
thrombolytics or ICU Stay.
USA Approval Date: 2017. 02.16.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 09.03.




Deep Vein Thrombosis (DVT)/Pulmonary Embolism (PE). TREAT: U
Apixaban Tablets.
(& Reduction in Risk of Recurrence After Initial TREAT.)
Oral Factor Xa Inhibitor AntiCoagulant.
EU Approval Date: 2014. 07.29.
USA Approval Date: 2014. 08.21.
(*) Companies; Patents; TradeMark & Web-Site Available on
Request.
UpDate: 2018. 01.29.




Deep Vein Thrombosis (DVT)/Pulmonary Embolism (PE). TREAT: D
Dabigatran Etexilate Capsules.
(& Reduction in Risk of Recurrence After Initial TREAT.)
Oral Direct Thrombin Inhibitor AntiCoagulant.
EU Approval Date: 2014. 06.06.
USA Approval Date: 2014. 04.07.
Patent No. 01 Expiration: 2018. 02.18.
(*) Company; Patents; TradeMark & Web-Site Available on
Request.
UpDate: 2018. 01.30.




Deep Vein Thrombosis (DVT)/Pulmonary Embolism (PE). TREAT: D
Dabigatran Etexilate Capsules.
(& Reduction in Risk of Recurrence After Initial TREAT.)
Oral Direct Thrombin Inhibitor AntiCoagulant. REVERSAL: IdarucizuMAb
IV Injection 5 g.
USA Approval Date: 2015. 10.16.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 04.18.




Deep Vein Thrombosis (DVT)/Pulmonary Embolism (PE). TREAT:
Enoxaparin Sodium Injection. BRAND.
low molecular weight heparin [LMWH].
Patent Expiration: 2004.
(*) Company : Sanofi Aventis US LLC.
TradeMark: Lovenox
Web-Site : www.lovenox.com
UpDate: 2018. 01.31.




Deep Vein Thrombosis (DVT)/Pulmonary Embolism (PE). TREAT:
Enoxaparin Sodium Injection. GENERIC.
low molecular weight heparin [LMWH].
USA Approval Date: 2010. 07.
(*) Company : Momenta Pharmaceuticals.
Web-Site: www.momentapharma.com/products/enoxaparin.php
UpDate: 2018. 01.31.




Deep Vein Thrombosis (DVT)/Pulmonary Embolism (PE). TREAT:
Fondaparinux Sodium.
Synthetic Heparin.
Xa Inhibitor.
(*) Company : Aspen Holdings. www.aspenpharma.com
Patents : Expiration Year: 2002.
TradeMark: Arixtra.
Web-Site : www.aspenpharma.com/thrombosis/
UpDate: 2018. 02.01.




Deep Vein Thrombosis (DVT)/Pulmonary Embolism (PE). TREAT: D
Rivaroxaban Tablets.
(& Reduction in Risk of Recurrence After Initial TREAT.)
Xa Inhibitor.
USA Approval Date: 2012. 11.02.
(*) Companies; Patents; TradeMark & Web-Site Available on
Request.
UpDate: 2018. 02.04.




DIAG. Reagents.
(*) Company; Patent & Web-Site Available on Request.
UpDate: 2018. 01.29.




DxH 900 Hematology Analyzer.
System helps laboratories deliver fast, accurate results through near native-state cellular characterization, precise flagging and a 93% first-pass throughput
Available for Sale in AU; CA; EU; USA
& NZ.
(*) Company: Beckman Coulter.
www.BeckmanCoulter.com
UpDate: 2018. 05.02.




Essential Thrombocythemia (ET). Treat.:
Anagrelid.HCl Tab.
Available in DE; DK; IS; NO; RU & UK
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 01.16.




Hemophagocytic LymphoHistiocytosis.
Treat.: EmapaluMAb.
USA Approval Date: 2018. 11.20.
(*) Company : Swedish Orphan Biovitrum
TradeMark: Gamifant.
Web-Site : gamifant.com
UpDate: 2018. 11.21.




Hemophilia A. TREAT.: Antihemophilic Factor (Recombinant).
(*) Company : Bayer AG.
Patents : Expired
TradeMark: Kogenate
Web-Site : www.kogenatefs.com
UpDate: 2018. 02.01.




Hemophilia A. TREAT.: Antihemophilic Factor (Recombinant). (C>S)
Approved in CA; EU; USA Etc.
PharmacoKinetic Dosing Software:
EU Approval Date: Since 2014.
USA Approval Date: 2017. 12.19.
(*) Company; TradeMarks & Web-Site
Available on Request.
UpDate: 2017. 12.20.




Hemophilia A. TREAT.: Antihemophilic
Factor (Recombinant). (D)
CA Approval Date : 2016. 02.03.
EU Approval Date : 2016. 02.18.
USA Approval Date: 2016. 03.17.
(*) Company : Bayer.
TradeMark: Kovaltry.
Web-Site : www.kovaltry-us.com
UpDate: 2018. 08.31.




Hemophilia A. TREAT.: Antihemophilic Factor (Recombinant). PEGylated. (C>S)
EU Approval Date : 2018. 01.15.
USA Approval Date: 2015. 11.13.
(*) Company; TradeMarks & Web-Site
Available on Request.
UpDate: 2018. 01.16.




Hemophilia A. TREAT.: Antihemophilic Factor (Recombinant). PEGylated. (D)
EU Approval Date: 2018. 11.27.
USA Approval Date: 2018. 08.30.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 08.14.




Hemophilia A. TREAT.: EmicizuMAb-kxwh>
Hemo A with Factor VIII Inhibitors. (U)
CA Approval Date : 2018. 08.07.
USA Approval Date: 2017. 11.16.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 08.08.




Hemophilia A. TREAT.: Recombinant Fac-
tor VIII (rFVIII). (C>O)
EU Approval Date : 2018. 06.18.
[New single dose vial strengths of 2500, 3000 and 4000 International Units (IU)]
USA Approval Date: 2015. 09.14.
(*) Company; Patents & TradeMark Avai-
lable on Request.
UpDate: 2018. 06.19.




Hemophilia B. TREAT.: NonaCog Beta Pegol
[Coagulation Factor IX (Recombinant)
GlycoPEGylated.]
CA Launch Date: 2018. 04.11.
USA Approval Date: 2017. 05.31.
USA Launch Date: 2018. 02.08.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 04.12.




Heparin Na Injection. (Generic).
Heparin is a complex injectable used as an anticoagulant in blood transfusions, extracorporeal circulation and dialysis procedures to prevent and treat various types of blood clots and to treat atrial fibrillation with embolization.
USA Approval Date: 2017. 12.01.
(*) Company Available on Request.
UpDate: 2017. 12.05.




Hereditary AntiThrombin Deficiency. Prevention:
AntiThrombin Recombinant.
EU Approval Date : ?
USA Approval Date: 2009. 02.06.
(*) Company; Patents; TradeMark & Web-Site Available on
Request.
UpDate: 2018. 01.29.




Human Factor Xa.
(*) Company : Enzyme Research Laboratories.
Web-Site: www.enzymeresearch.com/product/human-factor-
xa/
UpDate: 2018. 01.31.




Platelet Transfusions. Pathogen Reduced Platelets Offering.
(*) Company: Versiti Inc. www.versiti.org
UpDate: 2018. 02.22.




Pulmonary Embolism (PE). TREAT.:
Thrombectomy Device.
USA Approval Date: 2018. 05.21.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 09.03.




Rivaroxaban. AntiDote. (U)
EU Approval Date: 2019. 04.26.
USA Approval Date: 2018. 05.03.
(*) Company; Patents; TradeMarks & Web-
Site Available on Request
UpDate: 2020. 05.06.




Sickle Cell Disease. TREAT.: Hydroxy-
Urea.
EU Approval Year : 2007.
USA Approval Date: 2018. 08.21.
(*) Company : AddMedica. (FR)
Licensee USA: Medunik USA
TradeMark : Siklos
Web-Site :
www.addmedica.com/Global-Siklos
UpDate: 2018. 08.22.




Sickle Cell Disease. TREAT.: L-Glutamine Oral Powder.
IL Approval Date: 2020. 06.29.
USA Approval Date: 2017. 07.07.
USA Launch Date : 2017. 12.11.
(*) Company; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 06.30.




ThromboCythemia. Essential ThromboCythemia. TREAT.: (I)
Anagrelide.HCl.
Approved in ..
(*) Company; Patents & TradeMarks Available on Request.
UpDate: 2018. 02.02.




ThromboCytopenia. Chronic Liver Disease
Scheduled to Undergo Procedure. Treat.:
Lusutrombopag 1/Day Oral. (J)
Thrombopoietin (TPO) Receptor Agonist.
JP Approval Date : 2015. 09.
USA Approval Date: 2018. 08.01.
USA Launch Date: 2018. 08.30.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 08.31.




Transfusion Dependent Beta Thalassaemia.
(TDT). Gene Therapy.
EU Conditional Approval: 2019. 03.25.
(*) Company : Bluebird Bio.
TradeMark: Zynteglo.
UpDate: 2019. 03.26.




Vascular Surgery>Pulmonary Embolism (PE). Prevention: Vena Cava Filter.
USA Approval Date: 2014. 01.16.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 04.17.




Vascular Surgery>Pulmonary Embolism (PE). Prevention: Vena Cava Filter. Retrieval Kits.
USA Launch Date: 2020. 01.22.
(*) Company; Patents & Web-Site Avai-
laible on Request.
UpDate: 2020. 04.17.




Vascular Surgery>Pulmonary Embolism (PE). Prevention: Vena Cava Filter. Retrieval System.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 04.19.




>HEMATOLOGY.'s products
This section has no products